Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (257)

« Back to Publications

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.

Muller P. et al, (2026), Diabetes Obes Metab

Participants' experiences of living with cystic fibrosis related diabetes and using a hybrid closed-loop system to support self-management: qualitative study.

Lawton J. et al, (2026), BMC Endocr Disord

Association between urban ecological environment quality, socioeconomic disparity, and incidence of type 2 diabetes among middle-aged and elderly populations in the United Kingdom

Gu J. et al, (2026), Landscape and Urban Planning, 271

2279-P: Hemoglobin A1c and Risk of Death in CF-Related Diabetes: A UK CF Registry Study

ADLER AI. et al, (2026), Diabetes, 75

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data.

Lugo-Palacios DG. et al, (2026), Health Technol Assess, 30, 1 - 28

Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial.

Gao R. et al, (2026), EBioMedicine, 128

Analogue insulin, GLP-1, and the WHO Model Essential Medicines List - Authors reply.

Beran D. et al, (2026), Lancet Diabetes Endocrinol, 14, 377 - 378

Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.

Zeng G. et al, (2026), Lancet, 407, 1626 - 1638

Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.

Passos PRC. et al, (2026), Diabetes Care

Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.

Bidel Z. et al, (2026), Eur Heart J, 47, 1649 - 1657

Challenges and Recommendations for Integrating Circadian Medicine in Critical Care: A Roadmap.

Hiemstra FW. et al, (2026), Chest, 169, 977 - 990

Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.

Coleman RL. et al, (2026), Diabetes Obes Metab, 28, 1068 - 1075

Has the WHO Model Essential Medicines List lost its way?

Beran D. et al, (2025), Lancet Diabetes Endocrinol, 13, 999 - 1000

Assessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database.

Hanlon P. et al, (2025), BMC Med, 23

International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.

Clarke PM. et al, (2025), Diabetes Care, 48, 1925 - 1931

Load More

1
2
3
4
5
6
7
...
»